The recent selling looked more like profit taking due to uncertainty of results than insider selling, the volume was relatively low. Macrilen is difficult to screw up and Zoptrex, after passing the last interim analysis, has at least 40%-50% chance of success, and given the large multi-bagger potential (15x-20x from here for Zoptrex alone) this presents great pot odds. The problem will be if Macrilen fails and the stock drops, and suddenly Zoptrex is the only shot on goal left. That will take balls of steel to hold, but right now a small-to-medium sized bet makes sense. Even if only Macrilen succeeds the pps should double given projected sales potential for Macrilen (maybe factor in a little dilution for commercialization). Yeah, history looks horrid for AEZS, but this is pretty much the only time a bet made sense. Good luck and HNY!